158 related articles for article (PubMed ID: 24340082)
21. Prognostic factors in node-negative male breast cancer.
Avisar E; McParland E; Dicostanzo D; Axelrod D
Clin Breast Cancer; 2006 Oct; 7(4):331-5. PubMed ID: 17092401
[TBL] [Abstract][Full Text] [Related]
22. [The prognostic significance of cathepsin D in primary breast cancer].
Crombach G; Ingenhorst A; Göhring UJ; Scharl A; Schaeffer HJ; Stützer H; Bolte A
Geburtshilfe Frauenheilkd; 1994 Oct; 54(10):545-51. PubMed ID: 8001750
[TBL] [Abstract][Full Text] [Related]
23. Association of sonographic features and molecular subtypes in predicting breast cancer disease outcomes.
Wang H; Yao J; Zhu Y; Zhan W; Chen X; Shen K
Cancer Med; 2020 Sep; 9(17):6173-6185. PubMed ID: 32657039
[TBL] [Abstract][Full Text] [Related]
24. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.
Ma F; Ding X; Fan Y; Ying J; Zheng S; Lu N; Xu B
PLoS One; 2014; 9(11):e112765. PubMed ID: 25393310
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
26. High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy.
Zurrida S; Bagnardi V; Curigliano G; Mastropasqua MG; Orecchia R; Disalvatore D; Greco M; Cataliotti L; D'Aiuto G; Talakhadze N; Goldhirsch A; Viale G
Eur J Cancer; 2013 Oct; 49(15):3083-92. PubMed ID: 23777741
[TBL] [Abstract][Full Text] [Related]
27. Prognostic and predictive value of Ki-67 in triple-negative breast cancer.
Wang W; Wu J; Zhang P; Fei X; Zong Y; Chen X; Huang O; He JR; Chen W; Li Y; Shen K; Zhu L
Oncotarget; 2016 May; 7(21):31079-87. PubMed ID: 27145269
[TBL] [Abstract][Full Text] [Related]
28. Axillary lymph node micrometastases decrease triple-negative early breast cancer survival.
Houvenaeghel G; Sabatier R; Reyal F; Classe JM; Giard S; Charitansky H; Rouzier R; Faure C; Garbay JR; Daraï E; Hudry D; Gimbergues P; Villet R; Lambaudie E
Br J Cancer; 2016 Oct; 115(9):1024-1031. PubMed ID: 27685443
[TBL] [Abstract][Full Text] [Related]
29. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.
Harbeck N; Dettmar P; Thomssen C; Berger U; Ulm K; Kates R; Höfler H; Jänicke F; Graeff H; Schmitt M
Br J Cancer; 1999 May; 80(3-4):419-26. PubMed ID: 10408848
[TBL] [Abstract][Full Text] [Related]
30. Expression of Ki-67 and Estrogen Receptor Beta in Primary Cutaneous Melanoma as a Potential Indicator of Regional Lymph Node Positivity.
Udovicic-Gagula D; Ahmovic A; Bilalovic N; Doric M
Appl Immunohistochem Mol Morphol; 2019 Jan; 27(1):27-32. PubMed ID: 28549035
[TBL] [Abstract][Full Text] [Related]
31. Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators.
Lah TT; Cercek M; Blejec A; Kos J; Gorodetsky E; Somers R; Daskal I
Clin Cancer Res; 2000 Feb; 6(2):578-84. PubMed ID: 10690542
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years.
Mirza AN; Mirza NQ; Vlastos G; Singletary SE
Ann Surg; 2002 Jan; 235(1):10-26. PubMed ID: 11753038
[TBL] [Abstract][Full Text] [Related]
33. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
35. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
Abd-Elazeem MA; Abd-Elazeem MA
Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
[TBL] [Abstract][Full Text] [Related]
36. Traditional and new prognosticators in breast cancer: Nottingham index, Mib-1 and estrogen receptor signaling remain the best predictors of relapse and survival in a series of 289 cases.
Megha T; Neri A; Malagnino V; Caruso S; Onorati M; Roviello F; Tosi P
Cancer Biol Ther; 2010 Feb; 9(4):266-73. PubMed ID: 20026902
[TBL] [Abstract][Full Text] [Related]
37. A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol.
Pujol P; Maudelonde T; Daures JP; Rouanet P; Brouillet JP; Pujol H; Rochefort H
Cancer; 1993 Mar; 71(6):2006-12. PubMed ID: 8443752
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer.
Munzone E; Botteri E; Sciandivasci A; Curigliano G; Nolè F; Mastropasqua M; Rotmensz N; Colleoni M; Esposito A; Adamoli L; Luini A; Goldhirsch A; Viale G
Breast Cancer Res Treat; 2012 Jul; 134(1):277-82. PubMed ID: 22467243
[TBL] [Abstract][Full Text] [Related]
39. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
40. Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis.
Perez CA; Zumsteg ZS; Gupta G; Morrow M; Arnold B; Patil SM; Traina TA; Robson ME; Wen YH; McCormick B; Powell SN; Ho AY
Breast Cancer Res Treat; 2013 Jun; 139(2):497-506. PubMed ID: 23645006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]